Tweet
Ann Vasc Dis
. 2024 Mar 25;17(1):1-8.
doi: 10.3400/avd.oa.23-00031. Epub 2023 Nov 28. Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study
Yugo Yamashita 1 , Sen Yachi 2 , Makoto Takeyama 2 , Yuji Nishimoto 3 , Ichizo Tsujino 4 , Junichi Nakamura 4 , Naoto Yamamoto 5 , Hiroko Nakata 6 , Satoshi Ikeda 7 , Michihisa Umetsu 8 , Shizu Aikawa 9 , Hiroya Hayashi 10 , Hirono Satokawa 11 , Yoshinori Okuno 1 , Eriko Iwata 12 , Yoshito Ogihara 13 , Nobutaka Ikeda 14 , Akane Kondo 15 , Takehisa Iwai 16 , Norikazu Yamada 17 , Tomohiro Ogawa 18 , Takao Kobayashi 5 , Makoto Mo 19 ; Clot-COVID Study Investigators
Affiliations
Objectives: The potential benefit of routine prophylactic anticoagulation for all hospitalized patients with clinically stable coronavirus disease 2019 (COVID-19) is still controversial. Method: The CLOT-COVID Study was a multicenter observational study enrolling 2894 consecutive hospitalized patients with COVID-19. The current study population consisted of 1738 hospitalized patients with mild COVID-19 at admission not requiring oxygen administration, who were divided into 2 groups: patients with prophylactic anticoagulation (n = 326) and those without (n = 1412). Results: Patients with prophylactic anticoagulation had more severe status of the worst severity of COVID-19 during hospitalization compared with those without (mild: 38% versus 82%, moderate: 55% versus 17%, and severe or death at discharge: 6.4% versus 0.7%, P <0.001). During hospitalization, 8 patients (0.5%) developed thrombosis, and the incidences of thrombosis were numerically higher in patients with more severe status of worst severity of COVID-19 during hospitalization (mild: 0.2%, moderate: 1.2%, and severe or death at discharge: 3.2%). Conclusions: Among hospitalized patients with clinically stable COVID-19 at admission, patients who did not worsen in COVID-19 severity after admission rarely developed thrombosis, although patients with worsening of COVID-19 severity after admission more often received prophylactic anticoagulation and might have a higher risk of thrombosis.
Keywords: COVID-19; anticoagulation; mild; stable; thrombosis.
. 2024 Mar 25;17(1):1-8.
doi: 10.3400/avd.oa.23-00031. Epub 2023 Nov 28. Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study
Yugo Yamashita 1 , Sen Yachi 2 , Makoto Takeyama 2 , Yuji Nishimoto 3 , Ichizo Tsujino 4 , Junichi Nakamura 4 , Naoto Yamamoto 5 , Hiroko Nakata 6 , Satoshi Ikeda 7 , Michihisa Umetsu 8 , Shizu Aikawa 9 , Hiroya Hayashi 10 , Hirono Satokawa 11 , Yoshinori Okuno 1 , Eriko Iwata 12 , Yoshito Ogihara 13 , Nobutaka Ikeda 14 , Akane Kondo 15 , Takehisa Iwai 16 , Norikazu Yamada 17 , Tomohiro Ogawa 18 , Takao Kobayashi 5 , Makoto Mo 19 ; Clot-COVID Study Investigators
Affiliations
- PMID: 38628927
- PMCID: PMC11018098
- DOI: 10.3400/avd.oa.23-00031
Objectives: The potential benefit of routine prophylactic anticoagulation for all hospitalized patients with clinically stable coronavirus disease 2019 (COVID-19) is still controversial. Method: The CLOT-COVID Study was a multicenter observational study enrolling 2894 consecutive hospitalized patients with COVID-19. The current study population consisted of 1738 hospitalized patients with mild COVID-19 at admission not requiring oxygen administration, who were divided into 2 groups: patients with prophylactic anticoagulation (n = 326) and those without (n = 1412). Results: Patients with prophylactic anticoagulation had more severe status of the worst severity of COVID-19 during hospitalization compared with those without (mild: 38% versus 82%, moderate: 55% versus 17%, and severe or death at discharge: 6.4% versus 0.7%, P <0.001). During hospitalization, 8 patients (0.5%) developed thrombosis, and the incidences of thrombosis were numerically higher in patients with more severe status of worst severity of COVID-19 during hospitalization (mild: 0.2%, moderate: 1.2%, and severe or death at discharge: 3.2%). Conclusions: Among hospitalized patients with clinically stable COVID-19 at admission, patients who did not worsen in COVID-19 severity after admission rarely developed thrombosis, although patients with worsening of COVID-19 severity after admission more often received prophylactic anticoagulation and might have a higher risk of thrombosis.
Keywords: COVID-19; anticoagulation; mild; stable; thrombosis.